Introduction
Local concentrations of reactants, intermediates, and enzymes dictate the rates and yields of all biochemical reactions. Controlling local concentrations in synthetic pathways is paramount for achieving satisfactory productivity of the desired products. Unlike natural pathways, exogenous synthetic pathways have not been adapted over eons to generate desirable products; overproduction of desirable products is rarely advantageous or necessary for survival in the host's native environments [1] . This divergence is further exacerbated as synthetic pathways become increasingly complex, introducing problems such as rapid diffusion and degradation of key intermediates, undesirable crosstalk with other cellular pathways, and accumulation of toxic metabolites that ultimately lower product yields [2] . To counter these issues, synthetic biologists have spatially organized pathway enzymes into supramolecular complexes in attempts to elevate local concentrations of enzymes and metabolites that improve reaction flux and minimize cross-reactions. To date, these efforts largely mimic natural metabolic control mechanisms that bring key components into close proximity [3, 4] .
Analogous to naturally occurring complexes, artificial assemblies of pathway enzymes co-localize multiple molecules to enhance substrate channeling and enzyme clustering effects (see [5] [6] [7] for previous reviews). The first attempts to mimic natural complexes are simple fusions of protein domains that catalyze successive reactions. While this strategy has led to increased productivity in multiple circumstances [8, 9] , it cannot be easily extended beyond two-reaction pathways. The strategy also precludes straightforward changes in enzyme stoichiometry, as catalytic domains are expressed in a fixed ratio on every fusion protein. Instead, synthetic biologists have taken a more modular approach using biomolecular scaffolds to co-localize target molecules [6] . Unlike simple fusions, catalytic domains are not covalently linked, but are co-localized through different interaction domains or physical sequestration. By decoupling binding domains and catalytic domains, generic scaffolds with multiple interaction sites can, in theory, be easily adapted to any number of synthetic pathways by simple substitution of binding and catalytic domains (Figure 1 ).
The potential advantages offered by this flexibility have driven the development of a wide variety of biomolecular scaffolds in recent years. Many of these scaffolds have been made from ''parts'' taken from interaction domains found in nature, especially protein-based scaffolds. Because the primary requirement to construct these scaffolds is proximity and interactions between the pathway enzymes, nucleic acids (DNA and RNA) [10, 11] and micro-compartments [12] have proven to be extremely useful as well.
Despite rapid advances in our ability to design biomolecular scaffolds a priori, particularly with nucleic acid-based scaffolds, precise assembly of synthetic pathways in vivo remains extremely challenging, primarily due to incomplete understanding of ligand-scaffold folding, unknown cross-interactions in the crowded intracellular environment, and complications resulted from adapting exogenous enzymes to host organisms. As we will discuss in this review, these challenges present both problems as well as opportunities that can be exploited using different scaffolding strategies.
Protein based scaffolds
In nature, organisms ranging from mammals to bacteria utilize enzyme complexes to optimize pathway performance [5] . The most striking examples of improved pathway efficiency by evolved enzyme complexes are those forming structures capable of physically channeling intermediates, such as carbamoyl phosphate synthase and tryptophan synthase [13] . These structures illustrate that physical tunnels can protect reactive intermediates from diffusion into the bulk solution and/or degradation from other cellular components. Another excellent example of multi-functional enzyme complexes is the natural cellulosomes of anaerobic cellulolytic bacteria [14] . Inspired by this natural metabolic complex, Liu et al. [15] exploited unique cohesin-dockerin interactions to assemble multi-enzyme methanol oxidation cascade containing three different NAD + -dependent dehydrogenases on the yeast cell surface. The NADH or electron production rate was five times higher than the unassembled enzyme mixture as a result of increased reaction rates facilitated by substrate channeling effects.
The most successful in vivo synthetic protein scaffolds for enhanced pathway efficiency to date are built from modular interaction domains using metazoan signaling proteins, which specifically recruit pathway enzymes tagged with their cognate interaction ligands. SH3, PDZ, and GBD domains were used by Dueber et al. [16] as interaction modules to construct synthetic protein scaffolds for mevalonate production in Escherichia coli. By optimizing synthetic scaffold expression levels to balance the scaffold to enzyme ratio and the stoichiometries of enzymes recruited to the synthetic complex, a mevalonate production E. coli strain was created with an astonishing 77-fold improvement in product titer [16] . The same set of scaffolds was applied inside E. coli cells to further improve glucaric acid productivity by about 5-fold compared to the non-scaffolded control pathway [17] . While this enhancement demonstrates the generalizability of this set of scaffolds, these results also highlight the fact that optimal scaffold architecture for different synthetic pathways will vary. To date, optimization remains highly empirical and mechanistic understanding of scaffold function still needs more exploration [18] .
Intuitively, scaffolding enhancement can be explained by proximity channeling, which involves two enzymes close enough such that the product of the former enzyme is processed by the second enzyme before it diffuses away. This mechanism has been used to explain the improvements in product titer by scaffold-mediated enzyme complexes [15] [16] [17] 19] . However, proximity channeling presents a fundamental problem: an enzyme can process the diffusing substrate only within the radius (0.1-1 nm) of the active site. Thus, the product of the first enzyme is unlikely to be processed by the second enzyme even if their active sites are only 10 nm apart [20] . As an alternative to the channeling hypothesis, Lee et al. [6] proposed a scaffold-mediated metabolite microdomain hypothesis. The central idea is that even though the intermediate produced by the former enzyme is unlikely to be processed by any individual downstream enzyme, the probability of the intermediate reacting with one of the many downstream enzymes in the micro-domain is high ( Figure 2a ) [21 ] . Because most enzymes naturally exist as oligomers, they can potentially form large metabolite micro-domains or enzyme agglomerates when they are bound onto multiple scaffolds [22] . For example, a PDZ domain and the corresponding PDZ ligand were used to assemble an octameric leucine dehydrogenase (LDH) with a dimeric formate dehydrogenase (FDH), providing the necessary NAD(H) recycling for the production of L-tert-leucine (Figure 2b) .
Because of the uncertainty surrounding the exact mechanism to enhance pathway efficiency, current efforts to construct protein-based scaffolds for any given synthetic pathways are, at best, inexact guesswork, and difficulties are further compounded by the complexity of the crowded intracellular environment. Expanding upon the successes of protein-based scaffolds, nucleic acidsbased scaffolds, which can offer a higher degree of predictability and may avoid many undesirable crossinteractions that are prevalent in protein-based scaffolds, have also been explored.
Nucleic acids based scaffolds
Use of nucleic acids as molecular scaffolds has gained a significant foothold with the advent of nucleic acid-based nanotechnology. Because DNA and RNA self-assemble in accordance to well-studied interactions, new structures can be readily designed computationally with high predictability [23, 24] and allows for the construction of complex nanostructures that can impose detailed spatial organization on bound proteins.
One of the first successful demonstrations of nucleic acids as a feasible medium for pathway scaffolding involved organizing the bienzyme cascade of glucose oxidase (GOx) and horseradish peroxidase (HRP) on a long linear DNA template with two alternating docking sequences [10] . GOx and HRP were chemically modified with DNA complementary to their respective docking sites on the linear DNA template (Figure 3a) . The GOx/HRP cascade was further applied to a two-dimensional DNA scaffold composed of ''hexagon-like'' structures [25] (Figure 3b ). Both designs enabled enzyme cascade activation while unassembled enzymes did not, a result attributed to the higher local intermediate concentrations achieved through closer enzyme proximity and further verified by another DNA origami tile scaffold study [26] . The 2D scaffolds, in particular, highlight how the rigidity of higher-dimensioned nucleic acid scaffolds provide advantages to guarantee structure and spacing over their more flexible 1D linear counterparts.
The biggest challenge for nucleic acid scaffolds has been the adaptation of in vitro models into an in vivo context. Enzyme-ligand fusions can form large metabolite micro-domains or enzyme agglomerates when they are bound onto multiple scaffolds. (a) Because many pathway enzymes naturally exist as oligomers, multimers of enzyme-ligand fusions can link with each other to form local regions of elevated metabolite concentrations and limit loss of intermediates. Quantitative modeling by Castellana et al. [30 ] suggests multi-enzyme clusters that may be formed by enzyme-scaffold complexes can achieve rapid processing of intermediates. (b) In this example, an octameric LDH and a dimeric LDH self-assemble into large complexes that facilitate 2-fold higher NADH-recycling efficiency and L-tert-leucine production by restricting NAD + /NADH diffusion out of micro-domains. Adapted from Gao et al. [22] .
Chemical modification techniques to link nucleic acids to enzymes in vitro can be costly and damaging to activity and are impossible to implement in vivo. Two alternative strategies for enzyme immobilization on nucleic acid scaffolds have emerged: nucleic acid binding protein domains [27 ,28,29] and aptamer binding interactions [11,30 ,31] . Zinc finger proteins (ZFPs), whose modular binding motifs can be engineered to recognize and bind double stranded DNA with high specificity [32] , has been successfully used in conjunction with DNA-guided scaffolds to achieve in vivo synthetic pathway enhancement in E. coli [27 ,28] . Conrado et al. used DNA scaffolds to enhance the production of three diverse metabolites: resveratrol, 1,2-propanediol, and mevalonate. By fusing ZFPs to pathway enzymes, chimeras were created and assembled onto their corresponding DNA sequences located on a plasmid DNA scaffold. The use of a plasmid DNA scaffold allowed for enzyme stoichiometry, order, and spacing to be optimized quickly and easily.
RNA scaffolds have struggled to adopt the same strategy as DNA scaffolds due to fewer well-characterized RNA binding domains of high binding affinity. Instead, by incorporating RNA aptamers, highly specific and strong RNA binding to aptamer ligands fused to enzymes of interest can be achieved. Using this aptamer approach, RNA scaffolds have been implemented successfully in vivo to organize [FeFe]-hydrogenase and ferredoxin for hydrogen production [11] . RNA scaffolds were self-assembled in E. coli containing two unique aptamer domains that bind to their corresponding hydrogenase and ferrodoxin aptamer-binding chimeras. Discrete, one-dimensional, and two-dimensional scaffold designs enhanced hydrogen yield by 4-, 11-, and 48-fold, respectively, compared to unscaffolded enzymes, further supporting that higher ordered scaffolds provide exponentially greater enhancement.
Beyond macrostructure, the helical nature of base pairing allows for the role of enzyme orientation to be studied. The same strategy for RNA scaffolding was adopted for the production of pentadecane involving the enzymes acyl-ACP reductase (AAR) and aldehyde deformylating oxygenase (ADO) [30 ] . The aptamer stem-loop length was modified to change the orientation of AAR and ADO with respect to each other. Even a one base pair difference (308 rotation) could reduce scaffolding enhancement from 2.4-fold to 1.5-fold, demonstrating that nuances such as enzyme active site orientation to directly channel intermediates towards the next enzyme in the cascade rather than away can have a profound impact.
The most complex pathway implemented thus far using an in vivo nucleic acid scaffold is a four-enzyme 2-D RNA scaffold system for an 88% increase in succinate titer [30 ] . While RNA based scaffolds tend to be less stable susceptible to degradation compared to DNA, transcription allows the expression of different single-stranded RNA for self-assembly. The ability to form higher-order dimensioned lattice scaffolds is crucial in achieving greater scaffolding effects., which falls in line with the scaffoldmediated metabolite microdomain hypothesis discussed in the previous section [21 ] . For 1D RNA scaffolds, only intermediates traversing on one particular ''line'' will encounter a downstream enzyme. Channeling intermediates down this ''line'' is ultimately difficult due to the flexible nature of the 1D design. In 2D and 3D RNA scaffolds, intermediates have a much higher probability of encountering their downstream enzyme partners in a manner directly proportional to the scaffold complexity because of the higher degree of enzyme clustering (Figure 3 ). Upcoming opportunities in this area are to design more complex architectures of higher-dimension to take advantage of macro-level enhancements from a metabolite microdomain and to create modular templates to quickly gain understanding and optimize particular pathways of interest in terms of spacing, ordering, stoichiometry, and orientation.
Micro-compartments
While spatial organization of enzymes on protein or nucleic acid scaffolds has enhanced metabolic pathway efficiency [35] , the possibility of losing intermediates/ cofactors to endogenous competing pathways remains a bottleneck for further improvement in efficiency [36] . Compartmentalization provides unique advantages of physical sequestration of limiting or toxic intermediates, selective control over substrate and product fluxes in and out of the compartment, and creation of a segregated environment that is more favorable for specific reactions (Figure 4) [36, 37] .
Natural compartments usually consist of a porous protein shell that encapsulates enzymes. Good examples found in nature are bacterial microcompartments (MCPs) [38] . They are composed of proteins forming a shell of roughly 100-150 nm in diameter, with a 4-16 nm central pore on the shell that control the selective diffusion of metabolites and sequester toxic intermediates on the basis of charge or polarity [39, 40] . For example, the carboxysome shell forms a barrier against CO 2 diffusion, which enhances carbon fixation efficiency [39] . With the discovery of targeting
Figure 4
Competing Enzyme
Microcompartment Cell

Current Opinion in Biotechnology
Micro-compartment confines pathway enzymes and intermediates into a physically isolated environment separate from other cell components. The isolated environment can be made to promote activities of the pathway enzymes within the compartment. This physical sequestration also protect enzyme and intermediate from losses due to competing reactions and degradation as well as elevating local concentrations of key molecules. As such, fluxes across the selective molecular barrier plays a significant role in the effectiveness of these scaffolds. peptides responsible for directing native cargo proteins into MCPs [41, 42 ] , heterologous proteins such as green fluorescent protein and b-galactosidase have been successfully targeted and encapsulated into synthetic MCPs [43] . Additionally, engineered lumazine synthase protein capsids have been used to encapsulate HIV proteases by Wö rsdörfer et al. [44] . Although synthetic MCPs encapsulating a complete heterologous metabolic pathway have not yet been reported, these works serve as the framework toward more complex MCPs. Beyond enzyme manipulation, MCPs provide opportunities to control metabolite and cofactor transport across MCP shells either by customizing the residues surrounding the pores for added selectivity or by creating chimeric MCP shells with altered permeability [37] .
Eukaryotes are naturally divided into intracellular compartments, and the use of mitochondria to encapsulate and cluster metabolic enzymes for enhanced pathway efficiency has been reported [45 ] . The native yeast Ehrlich pathway for isobutanol production is separated into subcellular compartments: the upstream enzymes (ILV1, ILV5, ILV3) are confined to the mitochondria to generate the intermediate a-ketoisovalerate (a-KIV), whereas the downstream enzymes (KDC and ADH) are confined to the cytoplasm. In this configuration, a-KIV transport across the membrane becomes a major bottleneck [36] . Avalos et al. targeted KDC and ADH into the mitochondria by using the N-terminal mitochondria localization signal sequence, thus compartmentalizing all involved enzymes and eliminating the need for intermediate transport across the mitochondrial membrane [45 ] . Higher local enzyme and intermediate (i.e. a-KIV) concentrations in the mitochondria led to a 260% enhancement in isobutaniol production compared to the native split configuration. Although similar strategies were used to implement isopentanol and 2-methyl-1-butanol pathways with 370% and 500% titer enhancement, respectively, effective use of mitochondria to host synthetic pathways is not always guaranteed, especially when substrates are not natively available or the native mitochondrial environment has unsuitable reaction conditions. Another potential barrier is the limited volume of most organelles relative to the whole organism [36] .
In addition to modifying natural compartments, synthetic micro-compartments can be created using viral-like particles (VLPs) [35, 46] , polymer cages [47] , or liposomes [48] . Regardless of molecular composition, all microcompartments are intended either to encapsulate the whole pathway for higher enzyme and intermediate concentrations, or to segregate the pathway into separate environments such that each component can function at higher efficiency. One promising approach is on the basis of the viral capsid derived from the bacteriophage [49, 50] . High-density encapsulation of different proteins within the engineered VLPs was demonstrated by coexpression of cargo-SP protein fusions with CP in E. coli [49] . A three-enzyme cascade catalyzing the conversion of lactose to glucose-6-phosphate was encapsulated within engineered P22 VLPs [51] . Although the overall enhancement is lower than similar scaffolding approaches, due to substantial differences in kinetic parameters among the enzymes, the P22 system provides a versatile platform for engineering synthetic MCPs for enzyme clustering.
Although ongoing research is promising, a universal platform of compartmentalization to enhance pathway efficiency remains elusive. As such, application of microcompartments to host synthetic pathways should be designed with considerations to substrate availability, enzyme-environment interactions, transport barriers, and local concentrations of both enzymes and intermediates.
Conclusions
Synthetic pathways are, by nature, a patchwork of enzymes with markedly different reaction kinetics [52] . Although rational optimization on the basis of modulating the absolute and relative expression levels of each enzyme has been met with some successes [53, 54] , the use of synthetic scaffolds for pathway organization has rapidly become a complementary and parallel approach to provide additional control over pathway fluxes by altering local enzyme stoichiometry. Regardless of biomolecular scaffolds employed, the central goal of exerting spatial control over enzyme clustering remains the same. While the benefit of co-localizing exogenous enzymes can be affected by many factors such as enzyme-scaffold interactions and differences in kinetic parameters, the importance of precise order and spacing of enzymes in the context of pathway enhancement remains debatable. This seeming paradox is readily observed by comparing the highly ordered nanostructures made with DNA/RNA scaffolds and the uncontrolled confinement of enzymes within micro-compartments. Before this paradox can be addressed, the experimental challenges to deconvolute multiple variables, such as relative distances, multimer interactions, and steric effects, must be met. The increasing use of nucleic acid-based scaffolds, which offer relatively predictable positional control and well-developed analytical techniques that can track single copies of DNA/ RNA molecules in vivo [55] , should allow for more thorough investigations. More importantly, the possibility to assemble DNA/RNA scaffolds that are structurally tunable should pave the way for dynamic flux control of enzyme cascades in response to environmental stimuli [56] .
